[go: up one dir, main page]

MX2018010483A - Inmunogenos para vacunacion contra vih. - Google Patents

Inmunogenos para vacunacion contra vih.

Info

Publication number
MX2018010483A
MX2018010483A MX2018010483A MX2018010483A MX2018010483A MX 2018010483 A MX2018010483 A MX 2018010483A MX 2018010483 A MX2018010483 A MX 2018010483A MX 2018010483 A MX2018010483 A MX 2018010483A MX 2018010483 A MX2018010483 A MX 2018010483A
Authority
MX
Mexico
Prior art keywords
immunogens
relates
hiv vaccination
vaccination
hiv
Prior art date
Application number
MX2018010483A
Other languages
English (en)
Inventor
Pujadas Beatriz Mothe
Anuska Llano
Christian Brander
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MX2018010483A publication Critical patent/MX2018010483A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos inmunógenos basados en péptidos solapantes (OLP) y péptidos derivados de los mismos útiles para la prevención y tratamiento de SIDA y sus enfermedades oportunistas relacionadas. La invención también se refiere a ácidos nucleicos aislados, vectores y células huésped que expresan estos inmunógenos así como vacunas que incluyen dichos inmunógenos.
MX2018010483A 2012-01-27 2014-07-25 Inmunogenos para vacunacion contra vih. MX2018010483A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12382031.8A EP2620446A1 (en) 2012-01-27 2012-01-27 Immunogens for HIV vaccination

Publications (1)

Publication Number Publication Date
MX2018010483A true MX2018010483A (es) 2020-09-02

Family

ID=47603800

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014009091A MX358711B (es) 2012-01-27 2013-01-28 Inmunogenos para vacunacion contra vih.
MX2018010483A MX2018010483A (es) 2012-01-27 2014-07-25 Inmunogenos para vacunacion contra vih.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014009091A MX358711B (es) 2012-01-27 2013-01-28 Inmunogenos para vacunacion contra vih.

Country Status (16)

Country Link
US (4) US9988425B2 (es)
EP (3) EP2620446A1 (es)
JP (2) JP6306514B2 (es)
KR (2) KR102108149B1 (es)
CN (2) CN110372798A (es)
AU (2) AU2013213564B2 (es)
BR (1) BR112014018396B1 (es)
CA (1) CA2862172C (es)
ES (1) ES2932407T3 (es)
IL (2) IL233771B (es)
IN (1) IN2014DN06164A (es)
MX (2) MX358711B (es)
NZ (3) NZ734689A (es)
RU (2) RU2648791C2 (es)
WO (1) WO2013110818A2 (es)
ZA (1) ZA201405204B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
TW201639852A (zh) 2008-12-09 2016-11-16 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US10072046B2 (en) * 2014-03-21 2018-09-11 Nutech Ventures Non-naturally occurring porcine reproductive and respiratory syndrome virus (PRRSV) and methods of using
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
UY36298A (es) 2014-09-16 2016-04-29 Gilead Science Inc Formas sólidas de un modulador del receptor tipo toll
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
CN114828884A (zh) * 2019-05-22 2022-07-29 埃利克斯疗法公司 用于疫苗的剂量方案
WO2020237027A1 (en) * 2019-05-22 2020-11-26 Gilead Sciences, Inc. Combination of a tlr7 modulating compound and an hiv vaccine
JP7454645B2 (ja) 2019-07-16 2024-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン並びにその作製方法及び使用方法
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
AU2021270777A1 (en) 2020-05-12 2022-11-10 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
CR20230312A (es) 2021-01-14 2023-08-31 Gilead Sciences Inc Vacunas contra el vih y métodos de uso
WO2024084441A1 (en) 2022-10-19 2024-04-25 Aelix Therapeutics, S.L. Combination hiv vaccine
EP4417974A1 (en) 2023-02-17 2024-08-21 Fundació Privada Institut de Recerca de la SIDA-Caixa Cd33 as a biomarker of hiv control
WO2025017540A1 (en) 2023-07-20 2025-01-23 Aelix Therapeutics, S.L. Method of treatment of hiv infection with vaccine
CN118389553A (zh) * 2024-03-01 2024-07-26 中国科学技术大学 免疫增效rna分子及其组合物、疫苗与试剂盒

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
US6858712B1 (en) 1984-08-22 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Cloning and expression of HTLV-III DNA
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5081226A (en) 1986-12-30 1992-01-14 The United States Of America As Represented By The Department Of Health And Human Services Synthetic peptides sharing sequence homology with the HIV envelope protein
US5976541A (en) 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US6210873B1 (en) 1987-08-28 2001-04-03 Board Of Regents, The University Of Texas System Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
GB8918200D0 (en) 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US7319000B1 (en) 1992-09-16 2008-01-15 Board Of Regents, The University Of Texas System Compositions and methods for eliciting immune or anti-infective responses
JPH08511007A (ja) 1993-06-09 1996-11-19 コノート ラボラトリーズ リミテッド タンデム合成ｈｉｖ−１ペプチド
PL192784B1 (pl) 1994-12-24 2006-12-29 Univ Cambridge Tech Zastosowanie kwasu nukleinowego
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6093400A (en) 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
CN1233187A (zh) 1996-08-09 1999-10-27 病毒技术公司 HIVp－17肽片段、含有该片段的组合物及其制造和使用方法
US6031647A (en) 1996-10-23 2000-02-29 Nortel Networks Corporation Stable power control for optical transmission systems
US5972339A (en) 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
US20040106136A1 (en) 1999-01-25 2004-06-03 Musc Foundation For Research Development Method for testing drug susceptibility of HIV
CN1297932A (zh) * 1999-11-30 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸
BR0016510A (pt) * 1999-12-23 2002-08-27 Medical Res Council Aperfeçoamentos em ou relacionados as respostas imunes ao hiv
FR2803307A1 (fr) 1999-12-30 2001-07-06 Centre Nat Rech Scient Lignees de lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo
US20040105871A1 (en) 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
CN1312275A (zh) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 一种新的多肽——人热休克蛋白15和编码这种多肽的多核苷酸
AU5929101A (en) 2000-04-28 2001-11-12 Us Gov Health & Human Serv Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
DE60026199T2 (de) 2000-05-18 2006-11-23 Geneart Ag Synthetische Gene für gagpol und deren Verwendungen
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
CA2419822C (en) * 2000-08-14 2011-02-08 Gary J. Nabel Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
CU23235A1 (es) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
IL160809A0 (en) 2001-09-20 2004-08-31 Glaxo Group Ltd HIV-gag CODON-OPTIMISED DNA VACCINES
AUPR842501A0 (en) 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
DE60325838D1 (de) 2002-03-19 2009-03-05 Glaxo Group Ltd Imidazoquinolinamine als adjuvantien für hiv dna vakzine
RU2238946C2 (ru) 2002-04-22 2004-10-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Искусственный белок-иммуноген tci, содержащий множественные ctl-эпитопы основных антигенов вич-1, искусственный ген tci, кодирующий полиэпитопный белок-иммуноген tci
EP1506223B1 (en) 2002-05-16 2005-11-16 Bavarian Nordic A/S Fusion protein of hiv regulatory/accessory proteins
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
PL218318B1 (pl) 2002-05-16 2014-11-28 Bavarian Nordic As Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
WO2004002415A2 (en) 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
NZ544011A (en) 2003-06-10 2009-02-28 Univ Melbourne Immunomodulating compositions uses therefor and processes for their production
CN102010463A (zh) 2003-09-17 2011-04-13 杜克大学 共有/祖先免疫原
US20070275010A1 (en) 2003-09-18 2007-11-29 Mark Feinberg Mva Vaccines
JP2007534302A (ja) * 2003-09-24 2007-11-29 オクソン セラピュティクス リミテッド Ｈｉｖ医薬
GB0323840D0 (en) 2003-10-10 2003-11-12 Ist Superiore Sanita Vaccines
EP1687022A4 (en) 2003-11-12 2008-02-13 Medical Res Council RENTA: HIV IMMUNOGEN, AND USES OF RENTA
US20090169503A1 (en) * 2004-07-09 2009-07-02 The Government Of The United States, As Represented By The Secretary Of Dept Of H&Hs Dna-based vaccination of retroviral-infected individuals undergoing treatment
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006026667A2 (en) 2004-08-27 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
US8000900B2 (en) 2004-09-21 2011-08-16 Microsoft Corporation Association-based predictions of pathogen characteristics
US20060095241A1 (en) 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US8478535B2 (en) 2004-10-29 2013-07-02 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060160070A1 (en) 2004-10-29 2006-07-20 Microsoft Corporation Association-based epitome design
JP5122983B2 (ja) 2005-02-24 2013-01-16 メディカル リサーチ カウンシル Ｈｉｖｃｏｎ：ｈｉｖ免疫原及びその使用
BRPI0613025A2 (pt) * 2005-07-11 2010-12-14 Globeimmune Inc composiÇço para reduzir a resistÊncia a um agente, mÉtodo para a preparaÇço de um veÍculo de levedura e uso da composiÇço
BRPI0504117A (pt) 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
KR20080106467A (ko) 2006-03-10 2008-12-05 펩트셀 리미티드 Ｈｉｖ 조절 또는 보조 단백질의 펩타이드, 그 조성물 및 이용 방법
GB0608368D0 (en) 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides
CA2670804A1 (en) 2006-05-19 2007-11-29 Sanofi Pasteur Inc. Immunological composition
WO2008142479A2 (en) 2006-08-25 2008-11-27 The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
US8198082B2 (en) 2007-03-28 2012-06-12 Hiroshima University Method of determining chicken embryonic stem cells
AU2008246139B2 (en) * 2007-04-26 2013-11-21 Merck Sharp & Dohme Llc Synthetic expression vectors for insect cells
WO2009009743A2 (en) * 2007-07-12 2009-01-15 Institute For Advance Study Sequence optimization for expression of a foreign gene
BRPI0821998A2 (pt) 2008-01-16 2019-08-27 Opal Therapeutics Pty Ltd composições de imunomodulação e usos para a mesma.
JP5984388B2 (ja) * 2008-07-16 2016-09-06 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン
EP2161279A1 (en) 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
US8709775B2 (en) 2008-08-29 2014-04-29 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
ES2699685T3 (es) 2008-11-18 2019-02-12 Beth Israel Deaconess Medical Ct Inc Vacunas antivíricas con inmunogenicidad celular mejorada
US20120308593A1 (en) 2009-09-17 2012-12-06 Sanofi Pasteur, Inc. Immunological Compositions for HIV
EA201270108A1 (ru) 2009-10-08 2012-08-30 Бавариан Нордик А/С Формирование полиспецифического t-клеточного ответа против вич у человека
EP2488649B1 (en) 2009-10-16 2019-04-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
WO2011082422A2 (en) 2010-01-04 2011-07-07 The Johns Hopkins University Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
CN103370333A (zh) 2010-11-10 2013-10-23 埃斯特韦实验室有限公司 高免疫原性hiv p24序列
EP2620446A1 (en) * 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2020237027A1 (en) 2019-05-22 2020-11-26 Gilead Sciences, Inc. Combination of a tlr7 modulating compound and an hiv vaccine
CN114828884A (zh) 2019-05-22 2022-07-29 埃利克斯疗法公司 用于疫苗的剂量方案
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Also Published As

Publication number Publication date
CA2862172C (en) 2023-07-18
JP6749357B2 (ja) 2020-09-02
EP4163290A1 (en) 2023-04-12
NZ723229A (en) 2019-03-29
BR112014018396A2 (es) 2017-06-20
KR20140122735A (ko) 2014-10-20
US11919926B2 (en) 2024-03-05
US9988425B2 (en) 2018-06-05
NZ628756A (en) 2016-12-23
RU2018104969A (ru) 2019-02-22
JP6306514B2 (ja) 2018-04-04
EP2620446A1 (en) 2013-07-31
IL233771A0 (en) 2014-09-30
IL268629B (en) 2021-06-30
US20190055289A1 (en) 2019-02-21
JP2018102314A (ja) 2018-07-05
RU2721274C2 (ru) 2020-05-18
AU2018203264A1 (en) 2018-05-31
BR112014018396B1 (pt) 2023-03-21
RU2648791C2 (ru) 2018-04-02
AU2013213564A1 (en) 2014-09-04
WO2013110818A3 (en) 2013-11-07
WO2013110818A2 (en) 2013-08-01
US20180170971A1 (en) 2018-06-21
CN110372798A (zh) 2019-10-25
BR112014018396A8 (pt) 2017-07-11
KR20190085552A (ko) 2019-07-18
KR102108149B1 (ko) 2020-05-12
CA2862172A1 (en) 2013-08-01
RU2018104969A3 (es) 2019-02-22
MX2014009091A (es) 2014-11-10
EP2807185B1 (en) 2022-09-14
CN104080800A (zh) 2014-10-01
ZA201405204B (en) 2015-10-28
NZ734689A (en) 2022-09-30
AU2013213564B2 (en) 2018-03-29
IN2014DN06164A (es) 2015-08-21
RU2014135053A (ru) 2016-03-27
IL268629A (en) 2019-10-31
HK1204632A1 (en) 2015-11-27
US11325946B2 (en) 2022-05-10
US20150050310A1 (en) 2015-02-19
ES2932407T3 (es) 2023-01-18
US10815278B2 (en) 2020-10-27
KR102140778B1 (ko) 2020-08-06
JP2015509707A (ja) 2015-04-02
EP2807185A2 (en) 2014-12-03
MX358711B (es) 2018-08-31
CN104080800B (zh) 2019-08-27
AU2018203264B2 (en) 2019-07-11
IL233771B (en) 2019-08-29
US20210246172A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
EP3741848A3 (en) Protease variants and polynucleotides encoding same
SG10201900948PA (en) Modified nucleotide linkers
PH12015501526B1 (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
GB201009222D0 (en) Improved cancer therapy based on tumour associated antigens derived from cyclin D1
EP3741849A3 (en) Protease variants and polynucleotides encoding same
IL236650B (en) Immunogenic combination, nucleic acids or vectors encoding it, host cells or compositions comprising them, and therapeutic uses thereof, process of producing an infectious virus and method for recombinant production of the mycobacterial antigens
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
GB0917002D0 (en) Improved shigella blebs
MX356647B (es) Polipeptidos que tienen actividad de fosfolipasa c y polinucleotidos que codifican los mismos.
WO2015052543A3 (en) Malaria vaccination
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
MX2021013104A (es) Variantes de lipasa y polinucleotidos que las codifican.
WO2014017493A9 (ja) ワクチン
GB201017519D0 (en) Vaccines
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
PH12015502353A1 (en) Fusion polypeptides and vaccines
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
MX2016012840A (es) Moléculas para transporte de antígeno modular mejoradas y sus usos.
MX360449B (es) Vacunas para el virus del papiloma humano y metodos para su uso.
MX2019007924A (es) Vacunas contra la influenza.
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same